The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| OCGN | +67.31% | +390.63% | +37.45% | -43% |
| S&P | +15.06% | +95.03% | +14.29% | +126% |
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.37M | 20.3% |
| Gross Profit | $0.45M | -20.8% |
| Gross Margin | 32.48% | -16.9% |
| Market Cap | $283.39M | -29.0% |
| Market Cap / Employee | $2.98M | 0.0% |
| Employees | 95 | 46.2% |
| Net Income | -$14.74M | 3.5% |
| EBITDA | -$12.87M | 13.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $27.01M | 72.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $31.97M | 527.1% |
| Short Term Debt | $0.85M | -51.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -120.97% | -40.2% |
| Return On Invested Capital | -96.74% | 15.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10.77M | -3.3% |
| Operating Free Cash Flow | -$10.73M | -8.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 15.09 | 5.75 | 6.94 | 17.81 | 35.11% |
| Price to Sales | 58.72 | 57.75 | 45.61 | 59.62 | -46.73% |
| Price to Tangible Book Value | 15.09 | 5.75 | 6.95 | 17.81 | 35.10% |
| Enterprise Value to EBITDA | -19.31 | -15.72 | -14.73 | -22.48 | -14.31% |
| Return on Equity | -103.3% | -154.0% | -249.0% | -570.0% | 374.89% |
| Total Debt | $6.78M | $32.50M | $31.82M | $32.82M | 378.12% |
OCGN earnings call for the period ending December 31, 2024.
OCGN earnings call for the period ending September 30, 2024.
OCGN earnings call for the period ending June 30, 2024.
OCGN earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
